Phase II study of Bendamustine-Rituximab therapy for CD20-positive untreated and advanced follicular lymphoma with poor response to R-CHOP therapy - Bendamustine Convert Study

Department of Hematology and Rheumatology,Kinki University Faculty of Medicine0 sites60 target enrollmentApril 24, 2014

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: untreated and advanced follicular lymphoma
Sponsor: Department of Hematology and Rheumatology,Kinki University Faculty of Medicine
Enrollment: 60
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

April 24, 2014

End Date

March 31, 2022

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Department of Hematology and Rheumatology,Kinki University Faculty of Medicine

•1\)Any other active malignancies 2\)Uncontrollable serious complications (diabetes, heart failure, cardiomyopathy, abnormal heart rhythm, angina, myocardial infarction, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, infection, a respiratory failure, an organic lung disease, hepatic insufficiency, liver cirrhosis, acute chronic hepatitis, renal insufficiency, etc.) patients with active tuberculosis 3\)Circulating lymphoma cells \>\= 25,000 /uL in peripheral blood 4\)Primary central nervous system lymphoma or central nervous system invasion 5\)Anaphylactic shock for any drugs 6\)The HCV antibody\-positive 7\)Inappropriate for rituximab treatment 8\)Serious mental disorder, such as schizophrenia 9\)Diagnosed as a malignant lymphoma, leukemia, and myelodysplastic syndromes in the past 10\)The treatment history of the chemotherapy, the radiotherapy, cytokine therapy, and antibody therapy to FL 11\)Pregnant/female patients who are unwilling to take prevention measures for contraception during treatment 12\)HIV antibody\-positive 13\)Inappropriate for entry by physician's decision